Entero-toxigenic Bacteroides fragilis contributes to intestinal barrier injury and colorectal cancer progression by mediating the BFT/STAT3/ZEB2 pathway

References

• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85. doi: 10.1001/jama.2021.0106
   PubMed Web of Science ®Google Scholar
• Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal barrier in human health and disease. Int J Environ Res Public Health. 2021;18(23):18. doi: 10.3390/ijerph182312836
   Web of Science ®Google Scholar
• Song C, Chai Z, Chen S, et al. Intestinal mucus components and secretion mechanisms: what we do and do not know. Exp Mol Med. 2023;55(4):681–91. doi: 10.1038/s12276-023-00960-y
   PubMed Web of Science ®Google Scholar
• An J, Liu Y, Wang Y, et al. The role of intestinal mucosal barrier in autoimmune disease: a potential target. Front Immunol. 2022;13:871713. doi: 10.3389/fimmu.2022.871713
   PubMed Web of Science ®Google Scholar
• Quaglio AEV, Grillo TG, De Oliveira ECS, et al. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 2022;28(30):4053–4060. doi: 10.3748/wjg.v28.i30.4053
   PubMed Web of Science ®Google Scholar
• Karpiński TM, Ożarowski M, Stasiewicz M. Carcinogenic microbiota and its role in colorectal cancer development. Semin Cancer Biol. 2022;86:420–30. doi: 10.1016/j.semcancer.2022.01.004
   PubMedGoogle Scholar
• Song M, Chan AT, Sun J. Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology. 2020;158(2):322–40. doi: 10.1053/j.gastro.2019.06.048
   PubMed Web of Science ®Google Scholar
• Pothuraju R, Chaudhary S, Rachagani S, et al. Mucins, gut microbiota, and postbiotics role in colorectal cancer. Gut Microbes. 2021;13(1):1974795. doi: 10.1080/19490976.2021.1974795
   PubMed Web of Science ®Google Scholar
• Shanahan F, Ghosh TS, O’Toole PW. The healthy microbiome—what is the definition of a healthy gut microbiome? Gastroenterology. 2021;160(2):483–494. doi: 10.1053/j.gastro.2020.09.057
   PubMed Web of Science ®Google Scholar
• Manos J. The human microbiome in disease and pathology. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. APMIS. 2022;130(12):690–705. doi: 10.1111/apm.13225
   PubMedGoogle Scholar
• Yang J, Li D, Yang Z, et al. Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families. Gut Microbes. 2020;11(4):918–29. doi: 10.1080/19490976.2020.1712986
   PubMed Web of Science ®Google Scholar
• Carrow HC, Batachari LE, Chu H, et al. Strain diversity in the microbiome: lessons from bacteroides fragilis. PLOS Pathogens. 2020;16(12):e1009056. doi: 10.1371/journal.ppat.1009056
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Front Immunol. 2020;11:615056. doi: 10.3389/fimmu.2020.615056
   PubMed Web of Science ®Google Scholar
• Clay SL, Fonseca-Pereira D, Garrett WS. Colorectal cancer: the facts in the case of the microbiota. J Clin Investig. 2022;132(4):132. doi: 10.1172/JCI155101
   Web of Science ®Google Scholar
• Tanaka T, Kohno H, Suzuki R, et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003;94(11):965–73. doi: 10.1111/j.1349-7006.2003.tb01386.x
   PubMed Web of Science ®Google Scholar
• Boleij A, Hechenbleikner EM, Goodwin AC, et al. The bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. 2015;60(2):208–15. doi: 10.1093/cid/ciu787
   PubMed Web of Science ®Google Scholar
• Shao X, Sun S, Zhou Y, et al. Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis. Cancer Lett. 2021;523:170–81. doi: 10.1016/j.canlet.2021.10.002
   PubMed Web of Science ®Google Scholar
• Liu QQ, Li CM, Fu LN, et al. Enterotoxigenic bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B. Gut Microbes. 2020;12(1):1788900. doi: 10.1080/19490976.2020.1788900
   PubMedGoogle Scholar
• Hwang S, Lee CG, Jo M, et al. Enterotoxigenic Bacteroides fragilis infection exacerbates tumorigenesis in AOM/DSS mouse model. Int J Med Sci. 2020;17(2):145–152. doi: 10.7150/ijms.38371
   PubMed Web of Science ®Google Scholar
• Lee YP, Huang WC, Lin TJ, et al. Toll-like receptor 4 prevents AOM/DSS-induced colitis-associated colorectal cancer in bacteroides fragilis gnotobiotic mice. Hum Exp Toxicol. 2021;40(4):622–633. doi: 10.1177/0960327120954249
   PubMed Web of Science ®Google Scholar
• Mootien S, Kaplan PM, Pizzo SV. Monoclonal antibodies specific for bacteroides fragilis enterotoxins BFT1 and BFT2 and their use in immunoassays. PloS One. 2017;12(3):e0173128. doi: 10.1371/journal.pone.0173128
   PubMed Web of Science ®Google Scholar
• Purcell RV, Permain J, Keenan JI. Enterotoxigenic bacteroides fragilis activates IL-8 expression through Stat3 in colorectal cancer cells. Gut Pathog. 2022;14(1):16. doi: 10.1186/s13099-022-00489-x
   PubMed Web of Science ®Google Scholar
• Xie X, Jiang D, Zhou X, et al. Recombinant bacteroides fragilis enterotoxin-1 (rBFT-1) promotes proliferation of colorectal cancer via CCL3-related molecular pathways. Open Life Sciences. 2021;16(1):408–18. doi: 10.1515/biol-2021-0043
   PubMed Web of Science ®Google Scholar
• Lee YK, Mehrabian P, Boyajian S, et al. The protective role of bacteroides fragilis in a murine model of colitis-associated colorectal cancer. mSphere. 2018;3(6):3. doi: 10.1128/mSphere.00587-18
   Web of Science ®Google Scholar
• Chan JL, Wu S, Geis AL, et al. Non-toxigenic bacteroides fragilis (NTBF) administration reduces bacteria-driven chronic colitis and tumor development independent of polysaccharide a. Mucosal Immunol. 2019;12(1):164–77. doi: 10.1038/s41385-018-0085-5
   PubMed Web of Science ®Google Scholar
• Jeon JI, Lee KH, Kim JM. Bacteroides fragilis enterotoxin upregulates matrix metalloproteinase-7 expression through MAPK and AP-1 activation in intestinal epithelial cells, leading to syndecan-2 release. Int J Mol Sci. 2021;22(21):22. doi: 10.3390/ijms222111817
   Web of Science ®Google Scholar
• Patterson L, Allen J, Posey I, et al. Glucosylceramide production maintains colon integrity in response to Bacteroides fragilis toxin-induced colon epithelial cell signaling. FASEB J. 2020;34(12):15922–15945. doi: 10.1096/fj.202001669R
   PubMed Web of Science ®Google Scholar
• Vernay T, Cannie I, Gaboriau F, et al. Bacteroides fragilis prevents Salmonella Heidelberg translocation in co-culture model mimicking intestinal epithelium. Benef Microbes. 2020;11(4):391–401. doi: 10.3920/BM2020.0004
   PubMed Web of Science ®Google Scholar
• Kim M, Morales LD, Jang IS, et al. Protein tyrosine phosphatases as potential regulators of STAT3 signaling. Int J Mol Sci. 2018;19(9):2708. doi: 10.3390/ijms19092708
   PubMed Web of Science ®Google Scholar
• Zou S, Tong Q, Liu B, et al. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19(1):145. doi: 10.1186/s12943-020-01258-7
   PubMed Web of Science ®Google Scholar
• Malki A, ElRuz RA, Gupta I, et al. Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements. Int J Mol Sci. 2020;22(1):22. doi: 10.3390/ijms22010130
   PubMed Web of Science ®Google Scholar
• Zhong Q, Fang Y, Lai Q, et al. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling. J Exp Clin Cancer Res. 2020;39(1):132. doi: 10.1186/s13046-020-01637-4
   PubMed Web of Science ®Google Scholar
• Wu X, Wei S, Chen M, et al. P2RY13 exacerbates intestinal inflammation by damaging the intestinal mucosal barrier via activating IL-6/STAT3 pathway. Int J Biol Sci. 2022;18(13):5056–5069. doi: 10.7150/ijbs.74304
   PubMed Web of Science ®Google Scholar
• Yan B, Mao X, Hu S, et al. Spermidine protects intestinal mucosal barrier function in mice colitis via the AhR/Nrf2 and AhR/STAT3 signaling pathways. Int Immunopharmacol. 2023;119:110166. doi: 10.1016/j.intimp.2023.110166
   PubMed Web of Science ®Google Scholar
• Wick EC, Rabizadeh S, Albesiano E, et al. Stat3 activation in murine colitis induced by enterotoxigenic bacteroides fragilis. Inflamm Bowel Dis. 2014;20(5):821–34. doi: 10.1097/MIB.0000000000000019
   PubMed Web of Science ®Google Scholar
• Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumor Biol. 2014;35(8):7335–7342. doi: 10.1007/s13277-014-2163-y
   PubMedGoogle Scholar
• Slowicka K, Petta I, Blancke G, et al. Zeb2 drives invasive and microbiota-dependent colon carcinoma. Nat Cancer. 2020;1(6):620–634. doi: 10.1038/s43018-020-0070-2
   PubMedGoogle Scholar